Prevention Of Substance Use Disorders
Summary
The act requires a health benefit plan, beginning January 1, 2022, to provide coverage for nonpharmacological treatment as an alternative to opioids. The required coverage must include, at a cost-sharing amount not to exceed the cost-sharing amount for a primary care visit for nonpreventive services and without a prior authorization requirement, at least 6 physical therapy visits, 6 occupational therapy visits,6 chiropractic visits, and 6 acupuncture visits per year. The act requires an insurance carrier (carrier) that provides prescription drug benefits to provide coverage, beginning January 1, 2022, for at least one atypical opioid that is approved by the federal food and drug administration (FDA) for the treatment of acute or chronic pain at the lowest cost-sharing tier of the carrier's formulary with no requirement for step therapy or prior authorization and to not require step therapy for any additional FDA-approved atypical opioids. The act precludes a carrier that has a contract with a physical therapist, occupational therapist, or acupuncturist from: Prohibiting the physical therapist, occupational therapist, or acupuncturist from, or penalizing the physical therapist, occupational therapist, or acupuncturist for, providing a covered person information on the amount of the covered person's financial responsibility for the covered person's physical therapy, occupational therapy, or acupuncture services; or Requiring the physical therapist, occupational therapist, or acupuncturist to charge or collect a copayment from a covered person that exceeds the total charges submitted by the physical therapist, occupational therapist, or acupuncturist. The commissioner of insurance is required to take action against a carrier that the commissioner determines is not complying with these prohibitions. The act requires the executive director of the department of regulatory agencies to promulgate rules that limit the supply of a benzodiazepine that a prescriber may prescribe to patient who has not had a prescription for benzodiazepine in the last 12 months. Current law limits an opioid prescriber from prescribing more than a 7-day supply of an opioid to a patient who has not had an opioid prescription within the previous 12 months unless certain conditions apply, and this prescribing limitation is set to repeal on September 1, 2021. The act continues the prescribing limitation indefinitely. The act requires the Colorado medical board (board) to consult with the center for research into substance use disorder prevention, treatment, and recovery support strategies to promulgate rules establishing competency-based continuing education requirements for physicians and physician assistants concerning prescribing practices for opioids. With regard to the prescription drug monitoring program (program), the act: Modifies requirements for adding prescription information to the program; (program) Prohibits the state board of pharmacy from charging practitioners or pharmacists a fee for registering or maintaining an account with the program; Continues indefinitely the requirement that a health care provider query the program before prescribing a second fill for an opioid; Requires each health care provider to query the program before prescribing a second fill for a benzodiazepine, unless certain exceptions apply; Requires the board to promulgate rules designating additional controlled substances and other prescription drugs to be tracked by the program; and In addition to current law allowing medical examiners and coroners to query the program when conducting an autopsy, allows medical examiners and coroners to query the program when conducting a death investigation. The act appropriates $18,540 from the division of professions and occupations cash fund to the department of regulatory agencies to implement the act, with $2,550 allocated to the Colorado medical board and $15,990 reappropriated to the department of law to provide legal services to the department of regulatory agencies. (Note: This summary applies to this bill as enacted.)
Bill status
vetoed
4 of 5 stages cleared
Introduction
Jan 2020
Committee Review
Jun 2020
House Passage
Jun 2020
Senate Passage
Jun 2020
Vetoed
Jul 2020
Introduced Jan 10, 2020
Vetoed Jul 2, 2020
Floor votes · Senate Jun 11, 2020 · House Jun 9, 2020
How they voted
20–14
Passed
Total votes 34
Jun 11, 2020
D
Democratic19
100% Yea
R
Republican15
93% Nay
Vote distribution
All Yea
All Nay
Mixed
No data
Full legislative history
Actions timeline
Total actions
16
Key actions
4
Committee
4
Jul 2, 2020
Vetoed
Governor Vetoed
executive
Jun 11, 2020
Senate · Passed
Senate Vote: pass (20-14)
senate
Jun 10, 2020
Upper · Passed
Senate Committee on Appropriations Refer Unamended to Senate Committee of the Whole
upper
Jun 10, 2020
Committee
Senate Committee on State, Veterans, & Military Affairs Refer Unamended to Appropriations
upper
Jun 9, 2020
House · Passed
House Vote: pass (58-3-4)
house
Jun 9, 2020
Introduced
Introduced In Senate - Assigned to State, Veterans, & Military Affairs
upper
Jun 8, 2020
Lower · Passed
House Committee on Appropriations Refer Amended to House Committee of the Whole
lower
Feb 19, 2020
Committee
House Committee on Health & Insurance Refer Amended to Appropriations
lower
Jan 10, 2020
Introduced
Introduced In House - Assigned to Health & Insurance
lower
4 primary · 0 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
CK
Chris Kennedy
DDemocratic
P
FW
Faith Winter
DDemocratic
P
KP
Kevin Priola
DDemocratic
P
LH
Leslie Herod
DDemocratic
Ask Maddy
·
AI policy assistant
Ask Maddy about HB 20-1085
Scope: CO
Hi! I can help you understand HB 20-1085. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline